Logo image
Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus-positive kidney transplant recipient
Journal article   Open access   Peer reviewed

Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus-positive kidney transplant recipient

D. H. Lee, G. E. Malat, T. E. Bias, M. N. Harhay, K. Ranganna and A. M. Doyle
Transplant infectious disease, v 18(4), pp 625-627
01 Aug 2016
PMID: 27159656
url
https://europepmc.org/articles/pmc5525135View
Accepted (AM)Open Access (License Unspecified) Open

Abstract

Immunology Infectious Diseases Life Sciences & Biomedicine Science & Technology Transplantation
Dolutegravir is a preferred antiretroviral drug for human immunodeficiency virus (HIV)-infected patients following solid organ transplantation. It has potent antiretroviral activity and does not interact with calcineurin inhibitors. We describe a case of an HIV-infected kidney transplant patient, who was noted to have a rising serum creatinine following initiation of dolutegravir. At first, an acute rejection episode was suspected, but this finding was later attributed to inhibition of creatinine secretion by dolutegravir. We suggest that an awareness of this potential effect of dolutegravir is important for providers who take care of HIV-positive kidney transplant recipients, in order to prevent potentially unnecessary testing.

Metrics

15 Record Views
11 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Immunology
Infectious Diseases
Transplantation
Logo image